UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~February 6~~March 30, 2026

Eikon Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-43085

84-2807586

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

230 Harriet Tubman Way


230 Harriet Tubman Way
Millbrae, California		94030
(Address of principal executive offices)		(Zip Code)

Millbrae, California 94030

(Address of principal executive offices)

(341) 777-0566

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencements communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		~~Trading Symbols~~TradingSymbols		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		EIKN		The Nasdaq Stock Market LLC

☒ Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


☒		Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

☐		If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

☐Item If2.02 anResults emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of ~~the~~Operations ~~Exchange~~and ~~Act~~Financial Condition.

~~Item~~On 5March 30, 2026, Eikon Therapeutics, Inc.03 ~~Amendments~~issued toa ~~Articles~~press release announcing clinical and corporate updates and its financial results for the three months and full year ended December 31, 2025 (the “Press Release”). A copy of ~~Incorporation~~the orPress ~~Bylaws;~~Release ~~Change~~is infurnished ~~Fiscal~~herewith ~~Year~~as Exhibit 99.1 and is incorporated by reference.

~~Amendment~~The information in this Item 2.02, including Exhibit 99.1 hereto, is being “furnished” and ~~Restatement~~shall not be deemed to be “filed” for purposes of ~~Certificate~~Section 18 of ~~Incorporation~~the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section or Section 11 and 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). The information in this Item 2.02, including Exhibit 99.1 hereto, shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act or into any filing or other document pursuant to the Exchange Act, except as otherwise expressly stated in any such filing.

In connection with the closing of the initial public offering (the “IPO”) of shares of common stock of Eikon Therapeutics, Inc. (the “Company”) on February 6, 2026, the Company filed an amended and restated certificate of incorporation (the “Restated Certificate”) with the Secretary of State of the State of Delaware. The Company’s board of directors (the “Board”) and stockholders previously approved the Restated Certificate to be effective as of immediately prior to the closing of the IPO.

Amendment and Restatement of Bylaws

Effective as of February 6, 2026, the Company adopted amended and restated bylaws (the “Restated Bylaws”) in connection with the closing of the IPO. The Board and stockholders previously approved the Restated Bylaws to be effective immediately prior to the closing of the IPO.

The foregoing descriptions of the Restated Certificate and Restated Bylaws are qualified in their entirety by reference to the full text of the Restated Certificate and Restated Bylaws, which are filed as Exhibits 3.1 and 3.2 hereto, respectively, and are incorporated herein by reference.

Item 9.01

Financial Statements and Exhibits.

(d)

Exhibits.

EXHIBITNUMBER		EXHIBIT DESCRIPTION
3.1		Amended and Restated Certificate of Incorporation of the Registrant.
99.1		Press Release, dated March 30, 2026.
3.2		Amended and Restated Bylaws of the Registrant (incorporated herein by reference to Exhibit 3.4 to the Registrant’s Registration Statement on Form S-1 (File No. 333-292633), filed with the Commission on January 9, 2026).
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Eikon Therapeutics, Inc. By: /s/ Roger M. Perlmutter, M.D., Ph.D. Roger M. Perlmutter, M.D., Ph.D. Chief Executive Officer

Dated: ~~February~~March 630, 2026

Filing Compare · Eikon Therapeutics, Inc.